25 sources checked · 2 source groups included · 1h ago
NBC News - US News reaches for "victory" where WYFF4 (Hearst, Greenville) stays flat.
STILL WATCHING
As of August 6, 2026 at 12:18 PM, this is how Optics News reads the wording differences in this story.
25 sources across 2 bias buckets agree on the event.
57/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
NBC News - US News · Center-left · News report
The Hill · Center · News report
Optics keeps watching for pickup.
SEE THE HEADLINES
The Food and Drug Administration (FDA) late Wednesday approved the nation's first m RNA flu vaccine, manufactured by drugmaker Moderna. The agency approved the shot for two separate age gro...
The Food and Drug Administration (FDA) late Wednesday approved the nation's first m RNA flu vaccine, manufactured by drugmaker Moderna.
The Food and Drug Administration (FDA) late Wednesday approved the nation's first m RNA flu vaccine, manufactured by drugmaker Moderna.
The agency approved the shot for two separate age groups: People age 50 to 64, and for 65 years and older.
A younger and higher-educated base were pivotal to Abdul El Sayed’s Senate Primary win, an analysis shows.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
Plus, what happens when you have an A.I. boss.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
SOURCE MAP CHANGES
Aug 6, 9:33 AM: KABC / ABC7 Los Angeles joined the source map.
Aug 6, 9:33 AM: WLS / ABC7 Chicago joined the source map.
Aug 6, 9:33 AM: KGO / ABC7 San Francisco joined the source map.
Aug 6, 9:33 AM: WPVI / 6abc Philadelphia joined the source map.
Now: Wording Gap is 57/99 and story health is live match · 25 sources · 2 buckets · comparable news format.